Viking Therapeutics Statistics
Share Statistics
Viking Therapeutics has 112.31M
shares outstanding. The number of shares has increased by 1.8%
in one year.
| Shares Outstanding | 112.31M |
| Shares Change (YoY) | 1.8% |
| Shares Change (QoQ) | 0.73% |
| Owned by Institutions (%) | 73.86% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 75,356 |
| FTD / Avg. Volume | 1.63% |
Short Selling Information
The latest short interest is 26.54M, so 23.63% of the outstanding
shares have been sold short.
| Short Interest | 26.54M |
| Short % of Shares Out | 23.63% |
| Short % of Float | 28.36% |
| Short Ratio (days to cover) | 5.84 |
Valuation Ratios
The PE ratio is -39.9 and the forward
PE ratio is -12.87.
Viking Therapeutics's PEG ratio is
-3.63.
| PE Ratio | -39.9 |
| Forward PE | -12.87 |
| PS Ratio | 0 |
| Forward PS | 3.5 |
| PB Ratio | 4.98 |
| P/FCF Ratio | -49.98 |
| PEG Ratio | -3.63 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Viking Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 33.09,
with a Debt / Equity ratio of 0.
| Current Ratio | 33.09 |
| Quick Ratio | 33.09 |
| Debt / Equity | 0 |
| Debt / EBITDA | -0.01 |
| Debt / FCF | -0.01 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-2,443,622.22 |
| Employee Count | 45 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -66.02% in the
last 52 weeks. The beta is 0.75, so Viking Therapeutics's
price volatility has been higher than the market average.
| Beta | 0.75 |
| 52-Week Price Change | -66.02% |
| 50-Day Moving Average | 26.5 |
| 200-Day Moving Average | 45.25 |
| Relative Strength Index (RSI) | 48.88 |
| Average Volume (20 Days) | 4,633,715 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -150.92M |
| Net Income | -109.96M |
| EBITDA | -109.52M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -1.01 |
Full Income StatementBalance Sheet
The company has 26.68M in cash and 1.12M in
debt, giving a net cash position of 25.56M.
| Cash & Cash Equivalents | 26.68M |
| Total Debt | 1.12M |
| Net Cash | 25.56M |
| Retained Earnings | -487.91M |
| Total Assets | 866.99M |
| Working Capital | 846.45M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -87.79M
and capital expenditures 0, giving a free cash flow of -87.79M.
| Operating Cash Flow | -87.79M |
| Capital Expenditures | n/a |
| Free Cash Flow | -87.79M |
| FCF Per Share | -0.81 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
